Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$9.97
+6.9%
$9.16
$4.58
$10.46
$494.44M1.61540,288 shs482,050 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$9.16
+5.4%
$7.52
$2.32
$9.88
$495.52M2.93562,441 shs154,077 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$6.12
+0.9%
$4.27
$0.60
$6.72
$497.31M1.451.10 million shs1.16 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$13.77
+0.9%
$11.91
$5.90
$18.17
$117.97M0.6320,288 shs3,061 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.85%-4.90%+7.87%+25.10%+30.72%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.69%-5.95%+24.14%+10.28%+143.42%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
+4.66%+38.67%+48.17%+181.86%+339.13%
Surrozen, Inc. stock logo
SRZN
Surrozen
-1.30%-0.80%+17.89%+62.38%+26.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$9.97
+6.9%
$9.16
$4.58
$10.46
$494.44M1.61540,288 shs482,050 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$9.16
+5.4%
$7.52
$2.32
$9.88
$495.52M2.93562,441 shs154,077 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$6.12
+0.9%
$4.27
$0.60
$6.72
$497.31M1.451.10 million shs1.16 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$13.77
+0.9%
$11.91
$5.90
$18.17
$117.97M0.6320,288 shs3,061 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.85%-4.90%+7.87%+25.10%+30.72%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-0.69%-5.95%+24.14%+10.28%+143.42%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
+4.66%+38.67%+48.17%+181.86%+339.13%
Surrozen, Inc. stock logo
SRZN
Surrozen
-1.30%-0.80%+17.89%+62.38%+26.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.82
Moderate Buy$12.5626.00% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.71
Moderate Buy$9.604.80% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.86
Moderate Buy$7.3319.88% Upside
Surrozen, Inc. stock logo
SRZN
Surrozen
2.33
Hold$38.50179.69% Upside

Current Analyst Ratings Breakdown

Latest SRZN, FULC, IMAB, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Surrozen, Inc. stock logo
SRZN
Surrozen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/3/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$9.00
10/3/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/27/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Surrozen, Inc. stock logo
SRZN
Surrozen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$10.00 ➝ $15.00
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M2.18N/AN/A$7.44 per share1.34
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M6.19N/AN/A$4.51 per share2.03
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M128.41N/AN/A$2.47 per share2.48
Surrozen, Inc. stock logo
SRZN
Surrozen
$12.62M9.35N/AN/A($6.55) per share-2.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.337.42N/AN/A37.21%-9.79%-5.42%11/6/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)
Surrozen, Inc. stock logo
SRZN
Surrozen
-$63.56M-$14.42N/AN/AN/A-274.42%-545.43%-64.40%11/5/2025 (Estimated)

Latest SRZN, FULC, IMAB, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29N/AN/AN/AN/AN/A
11/6/2025Q3 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23N/AN/AN/A$41.22 millionN/A
11/5/2025Q3 2025
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.17N/AN/AN/AN/AN/A
8/20/2025Q2 2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$0.10-$0.07+$0.03-$0.07N/AN/A
8/8/2025Q2 2025
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.23-$1.14+$0.09$2.55N/A$0.98 million
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Surrozen, Inc. stock logo
SRZN
Surrozen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
0.39
16.24
15.47
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.82
22.82
Surrozen, Inc. stock logo
SRZN
Surrozen
N/A
16.41
16.41

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Surrozen, Inc. stock logo
SRZN
Surrozen
66.57%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Surrozen, Inc. stock logo
SRZN
Surrozen
43.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.07 million45.01 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Surrozen, Inc. stock logo
SRZN
Surrozen
808.57 million4.84 millionNot Optionable

Recent News About These Companies

Surrozen (NASDAQ:SRZN) Trading Up 10.5% - Time to Buy?
Surrozen Reports Q2 Profit on Gains
Surrozen files to sell 5.21M shares of common stock for holders
Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$9.96 +0.65 (+6.92%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$9.16 +0.47 (+5.41%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$6.12 +0.06 (+0.94%)
As of 01:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Surrozen stock logo

Surrozen NASDAQ:SRZN

$13.76 +0.13 (+0.92%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.